Table 4 Examples of small molecule modulators for immune checkpoints
Name | Target | Research stage | Cancer types | References (First author, year) |
|---|---|---|---|---|
APBC A9 II-14 (d)PPA-1 | PD-1 binding to PD-L1 | Preclinical | Melanoma (in vitro) Colon cancer Colon cancer | Wang 2021 [260] Zhang 2021 [259] Fang 2021 [261] Chang 2015 [262] |
JQ-1 (BRD4i) eFT508 | The expression of PD-L1 | Phase I Phase I | Lymphoma Liver cancer | Zhu 2016 [263] Xu 2019 [264] |
PD-LYSO Curcumin Metformin | The degradation of PD-L1 | Preclinical Preclinical Preclinical | (in vitro) Breast cancer Breast cancer | Wang 2019 [265] Lim 2016 [266] Cha 2018 [267] |
CA-170 | VISTA and PD-1/PD-L1 inhibitor | Phase I | Advanced tumors and lymphomas | Sasikumar 2021 [268] |
NDI-101150 | MAP4K1 (HPK1) inhibitor | Phase I/II | Solid Tumors | You 2021 [269] |
NX-1607 | CBL-B inhibitor | Phase I | Advanced malignancies | Loeser 2007 [270] |
TNO155 | SHP2 inhibitor | Phase I/II | Advanced Solid Tumors | LaMarche 2020 [271] |